CRNX - Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study | Benzinga
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for acromegaly and CS.
Carcinoid syndrome occurs when a rare cancerous tumor, called a carcinoid tumor, secretes certain chemicals into your bloodstream, causing a variety of signs and symptoms.
"We are very encouraged by these strong initial findings in our Phase 2 study of paltusotine in people with carcinoid syndrome," said Scott Struthers, founder and CEO ...